Ancotil 500 mg

Quick links

Choose a section

Quick links to important sections

Advertisements

Ancotil 500 mg

Advertisements
Advertisements

Treatment option:

Advertisements

Overview of Ancotil 500 mg

Property Description
Active Ingredient Flucytosine (5-fluorocytosine)
Form Oral Tablet/Capsule, Intravenous Solution
Pharmacological Class Systemic Antifungal Agent, Antimetabolite
Common Use Treatment of serious systemic fungal infections
Origin Synthetic (fluorinated pyrimidine analogue)

What Type of Medicine is Ancotil 500 mg (Flucytosine)?

Ancotil 500 mg is a specialized, prescription-only medicine containing the active ingredient Flucytosine, which is chemically defined as a fluorinated pyrimidine analogue. The drug is fundamentally categorized as an antimetabolite and a systemic antifungal agent, designed to circulate throughout the body to combat infection. Flucytosine is clinically recognized for its efficacy against severe, disseminated fungal infections, known as systemic mycoses. Its primary therapeutic purpose is addressing serious illnesses, such as meningoencephalitis caused by Cryptococcus (cryptococcosis) or widespread invasive candidiasis, where deep-seated infection necessitates systemic pharmacological intervention.

Composition and Pharmaceutical Forms: The Role of 5-Fluorocytosine

The central component is the active ingredient Flucytosine, also known chemically as 5-fluorocytosine (5-FC). The 500 mg designation specifies the amount of Flucytosine contained in the standard oral dosage form, usually provided as a tablet or capsule. Although Ancotil is a single active ingredient product, its unique versatility is highlighted by the availability of an isotonic infusion solution for intravenous administration, allowing the same crucial active substance to be delivered rapidly in critical care settings.

How Does Flucytosine Work to Target Systemic Mycoses?

The mechanism of effect of Flucytosine is reliant on its function as a prodrug; it is inert until fungal cells take it up and convert it into the highly active substance 5-fluorouracil (5-FU). This metabolite selectively disrupts the fungus’s ability to build the necessary genetic material, resulting in antifungal activity. This unique action is why Flucytosine is almost universally administered as combination therapy with other antifungal agents. This combined approach is mandatory to maximize therapeutic outcome and prevent the development of resistance in serious systemic mycoses.

Regulatory References

  1. Flucytosine combination therapy (NIH/StatPearls)
Advertisements

What side effects are possible with Ancotil 500 mg?

Possible Side Effects and Safety Information

This information describes the documented safety profile of Ancotil (Flucytosine) 500 mg based on official government regulatory documents.


Documented Adverse Reactions

The most frequently reported adverse reactions affect the blood, liver, and gastrointestinal systems.

  • Common Reactions (may affect up to 1 in 10 people):

    • Nausea, vomiting, diarrhea.
    • Skin rash.
  • Serious and Clinically Significant Reactions (Frequency Not Defined/Known):

    • Blood and Bone Marrow Suppression (e.g., anemia, leukopenia, thrombocytopenia). This can be severe, irreversible, and potentially fatal, especially in immunosuppressed patients.
    • Hepatotoxicity (liver damage) including elevated liver enzymes (transaminases), acute hepatic injury, and hepatic necrosis.
    • Renal Impairment leading to azotemia, elevated BUN and creatinine, and renal failure.
    • Nervous System Effects: Confusion, hallucinations, sedation, peripheral neuropathy, and paresthesia.
    • Hypersensitivity reactions, including anaphylaxis.

Safety Restrictions and Monitoring

  • Contraindications: Ancotil is strictly contraindicated in patients with a known complete deficiency of the DPD (dihydropyrimidine dehydrogenase) enzyme due to the high risk of life-threatening toxicity.

  • Risk Mitigation: Extreme caution is required in patients with impaired renal function or existing bone marrow depression.

  • Exposure-Related Risk: The risk of serious toxicity (hematologic and hepatic) is closely linked to drug concentration in the blood, particularly if levels exceed 100,mu g/ mL.

  • Mandatory Monitoring: Regular and frequent monitoring of the following is required throughout treatment:

    • Complete blood cell counts.
    • Hepatic (liver) function tests.
    • Renal (kidney) function tests and serum drug concentrations.
  • Pregnancy and Breastfeeding: Use during pregnancy is restricted to situations where the potential benefit clearly justifies the potential risk to the fetus. Nursing must be discontinued if the drug is administered due to the risk of serious adverse reactions in the infant.

Advertisements

Overdose and Emergency Response

The official regulatory profile for an overdose of Ancotil (Flucytosine) focuses on the severe, concentration-dependent systemic toxicity that results from excessive exposure. Immediate medical attention is required if overdose is suspected or if signs of severe toxicity manifest.

Documented Overdose Manifestations

Overdose manifestations are primarily characterized by severe effects on the body’s critical systems. Documented presentations include severe hematological toxicity, such as leukopenia, thrombocytopenia, and bone marrow aplasia, which has been associated with death in susceptible patients. Other regulatory-listed effects involve hepatotoxicity, characterized by elevated liver enzymes, and neurotoxicity, which may present as confusion, hallucinations, or convulsions.

When to Seek Urgent Help and Management

Immediate medical attention is necessary upon suspicion of toxicity, which is strongly linked to prolonged serum concentrations exceeding 100 mu g/mL. Regulatory sources document that management involves stopping Flucytosine treatment and utilizing haemodialysis as a procedural measure to clear the dialysable drug from the circulation. Symptomatic and supportive treatment is officially advised.

Population-Specific Overdose Risks

The official labeling highlights particular risk factors. Patients with renal impairment face an increased risk of drug accumulation and progressive toxicity. Furthermore, individuals with Dihydropyrimidine Dehydrogenase (DPD) deficiency are at a high risk for life-threatening toxicity due to altered drug metabolism. Monitoring of plasma drug levels and hematopoietic function is required for all suspected cases.

Advertisements

Therapeutic Uses of Ancotil 500 mg

Quick Facts: Ancotil 500 mg Therapeutic Domains

  • Addresses serious fungal infections.
  • Employed in the management of infections caused by Candida strains.
  • Used for the care of conditions attributed to Cryptococcus strains, such as cryptococcal meningitis.
  • Utilized to contribute to the management of systemic fungal infections, often in combination with other medications.

Ancotil 500 mg (flucytosine) is a prescription medication authorized for the management of certain serious fungal infections. It is a therapy option used to address conditions caused by susceptible strains of two specific types of fungi, Candida and Cryptococcus.

This medication is primarily indicated for serious systemic infections. For example, it is used to support the care of cryptococcal meningitis and serious Candida infections that may involve the bloodstream, heart lining (endocarditis), or the urinary system. The medication is typically administered in conjunction with another antifungal agent. This practice is employed to help provide a robust approach to managing the infection and to assist in discouraging the development of resistance in the fungi.

Physicians may include this agent as a component of treatment for conditions like Candida septicemia, endocarditis, and certain urinary system infections, as well as pulmonary infections and meningitis caused by Cryptococcus. It is one of the systemic antifungal options recognized for its role in the therapeutic regimen for these concerns.

Advertisements

Eligibility and Restrictions for Use

Eligibility Profile: Ancotil (Flucytosine)

This section summarizes the official eligibility and non-eligibility information as documented in government regulatory labeling.


Populations for Whom Use is Contraindicated

Classification Status Rationale
Known complete Dihydropyrimidine Dehydrogenase (DPD) deficiency Contraindicated High risk of severe, life-threatening toxicity.
Hypersensitivity Contraindicated Known allergy to flucytosine or any excipients.
Physiological State Contraindicated Breastfeeding/Lactation.
Co-administration Contraindicated Concomitant use with irreversible DPD inhibitors (e.g., brivudine).

Populations Requiring Restricted or Conditional Use

Population/Condition Restriction/Requirement
Impaired Renal Function Requires extreme caution, mandatory regular monitoring of creatinine clearance, and dose adjustment.
Bone Marrow Suppression Requires extreme caution and strict clinical and laboratory monitoring due to high risk of haematologic damage.
Pregnancy Generally contraindicated, unless absolutely necessary for life-threatening infections where no alternative exists. Requires effective contraception for men and women of childbearing potential during and after treatment.
Paediatric Population Not recommended as first-line treatment or monotherapy; requires dose adjustment and strict monitoring of plasma levels.

Official Eligibility Conclusion: The profile is highly restrictive, primarily driven by the drug's metabolic pathway. Patients with complete DPD deficiency and breastfeeding women are strictly ineligible. Other groups, including those with compromised organ function (renal/hepatic) or blood disorders, may use the drug only under conditions of extreme caution and mandatory close monitoring to mitigate specific safety risks defined by the regulatory authorities.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Ancotil (Flucytosine) is critically defined by its metabolic and elimination pathways, leading to specific regulatory constraints for co-administration.

Contraindicated Combinations

The most significant restriction is the absolute prohibition against co-administering Flucytosine with irreversible inhibitors of Dihydropyrimidine Dehydrogenase (DPD), such as antiviral antiherpetic nucleoside analogues (brivudine or sorivudine). Flucytosine is partially converted to 5-fluorouracil (5-FU), and DPD inhibitors severely block 5-FU metabolism, leading to life-threatening toxicity.

Pharmacodynamic and Pharmacokinetic Interactions

Interacting Agent Category Practical Implication (Based on Regulatory Data)
Nephrotoxic Agents (e.g., Amphotericin B) Increase Flucytosine concentration by reducing renal clearance; requires strict renal function monitoring.
Myelosuppressive Agents (e.g., Zidovudine) Increased risk of haematological toxicity due to additive effects; requires enhanced blood count monitoring.
Cytarabine Inactivates Flucytosine's antifungal effect through competitive inhibition.

Timing and Population-Specific Notes

A minimum interval of 4 weeks must be observed between the end of treatment with DPD inhibitor analogues and the start of Flucytosine. The medicine is contraindicated in individuals with a known complete DPD enzyme deficiency due to the high risk of severe systemic toxicity.

Advertisements

Mechanism of Action

How Ancotil 500 mg Works

Selective Prodrug Activation and Cellular Entry

The mechanism hinges on a high degree of specificity of action by exploiting two key components unique to the fungal cell: the Cytosine Permease transporter, which facilitates entry of the inert prodrug Flucytosine (5-FC), and the enzyme Cytosine Deaminase, which converts 5-FC into the active metabolite 5-fluorouracil (5-FU). This mandatory activation sequence ensures that the destructive action is largely confining the destructive action to the fungal organism.

Dual Disruption of Fungal DNA and RNA Synthesis

The active metabolite, 5-FU, executes its effect by interfering with the fungus's ability to create genetic material and proteins. It is converted into the inhibitor 5-FdUMP, which blocks the enzyme Thymidylate Synthase to halt DNA synthesis, while simultaneously being misincorporated into fungal RNA, resulting in the production of non-functional proteins. This dual metabolic blockade prevents replication and induces cell death.

Mechanistic Synergy and Efficacy Constraint

The drug's mechanism is enhanced through synergy when co-administered with membrane-disrupting antifungals, as the enhanced membrane permeability boosts the initial uptake of 5-FC, resulting in higher intracellular concentrations for conversion. Conversely, the mechanism is severely constrained by fungal strains that develop resistance by losing the function of the activating enzymes, preventing the completion of the biochemical cascade.

Advertisements

Dosage and Administration Information

Official Administration and Dosage Principles

Ancotil (flucytosine) is officially administered via the oral route using 250 mg or 500 mg capsules or tablets. An intravenous infusion solution is also an approved form for use in specialized settings, typically delivered slowly over 20 to 40 minutes.

The core principle for correct use is the calculation of a total daily dose based on body weight, generally ranging from 50 to 150 mg/kg. This total must be divided into four equal doses and administered at fixed intervals, typically every six hours (q6h), to maintain effective concentration. The oral dose can be taken either with or without food.

Use Context and Dosage Adjustments

For the treatment of serious systemic infections, flucytosine is designated for use only in combination with another appropriate antifungal medication, such as amphotericin B.

A critical feature of flucytosine use is the requirement for Therapeutic Drug Monitoring (TDM). This involves measuring drug levels in the blood to ensure the mean steady-state concentration remains within the official target range of 35 to 70 μg/mL.

Furthermore, because the medicine is primarily cleared by the kidneys, the dosing interval must be modified in patients with renal impairment. The interval between doses (e.g., q6h, q12h, q24h) is specifically adjusted based on the measured Creatinine Clearance (CrCl) value. If a single dose is missed, patients are instructed not to take a double dose to compensate.

Advertisements

Recent Clinical Evidence

Research Evidence and Overview of Studies for Ancotil (Flucytosine)


Research Evidence for Cryptococcal Meningitis Treatment

The research base for flucytosine’s role in managing cryptococcal meningitis was evaluated in comprehensive studies, relying heavily on Randomized Controlled Trials (RCTs) and meta-analyses. These studies focus on flucytosine when it is observed in combination therapy regimens. Researchers have monitored key outcomes related to measurements of mortality rates at various short-term time points (e.g., 2 weeks and 10 weeks) and how the rate of fungal clearance, known as Early Fungicidal Activity (EFA), was measured from the spinal fluid in studies.

Research describes patterns observed in these studies where the addition of flucytosine to certain combination regimens was observed in some studies to correlate with lower measurements of mortality. Comparative trials described patterns where the flucytosine combination structure was associated with measurements showing a differential rate of fungal clearance in the central nervous system. These findings describe group patterns, particularly in adults with advanced HIV disease, and help contextualize the patterns related to this drug’s inclusion in initial treatment protocols.


Research Evidence for Severe Systemic Candidiasis

Flucytosine was studied for severe, disseminated infections caused by Candida species, collectively known as systemic candidiasis. This includes research exploring outcomes related to systemic or functional imbalance, such as bloodstream infections (septicemia), infections of the heart lining (endocarditis), and abdominal infections (peritonitis). Studies explored combination structures of flucytosine with amphotericin B alongside other single-agent treatments for evaluation.

These research scenarios focused on important outcomes related to pathogen eradication (clearing the fungus from the body) and the overall clinical response observed during the study period. For specific deep-seated infections, such as those in the abdomen, some randomized studies reported that the flucytosine combination structure was associated with more measurements of pathogen clearance. However, evidence quality varies across studies, and fewer large-scale RCTs exist for every possible infection site, meaning findings reflect the specific conditions under which they were conducted.


Overarching Research Principle: Combination Therapy

The entire evidence landscape for flucytosine describes the consistent principle that its research is structured around its use as a partner drug in combination. Research has consistently observed that when flucytosine was studied for systemic fungal infections as a single agent (monotherapy), the fungi developed resistance to the drug quickly and frequently.

Therefore, the available research strongly describes the use of flucytosine as a component of a two-drug approach. This strategy was observed in studies as an approach designed to maximize the fungicidal activity and prevent the emergence of resistance. Research provides context on why flucytosine is typically studied and utilized in a combined structure, and data for systemic monotherapy are still emerging or evidence is limited due to this high risk of resistance.


Long-Term Outcomes and Follow-up in Clinical Research

The majority of pivotal trials for flucytosine focus on outcomes measured over short to intermediate periods, generally spanning the acute treatment phase of up to 10 weeks or 3 months. Follow-up durations were limited in many primary studies, as the goal was evaluated in the immediate response to the administration structure.

Consequently, there is limited information for long-term outcomes that track patients for years after the initial research period. While studies sometimes monitored patient survival after 10 weeks, the evidence concerning the patterns related to sustained outcomes or functional outcomes over extended periods is not fully established. Research does not determine whether an individual will maintain the observed response years later.


Evidence Reviewed in Special Patient Populations

Research has explored flucytosine's use in several special patient groups where fungal infections pose a high risk. Studies were conducted during periods of increased symptom activity in patients with advanced HIV disease (AIDS), particularly concerning cryptococcal meningitis. Observational research also describes patterns related to the drug's inclusion in regimens for groups like Intensive Care Unit (ICU) patients with systemic Candida infections.

However, data for certain groups remain insufficient. For instance, while flucytosine was studied for some non-systemic conditions like Candida urinary tract infections, these are often smaller, older studies. Furthermore, comparative evidence is lacking for many specific patient subgroups defined by other underlying illnesses or comorbidities.


Key Uncertainties and Research Gaps in the Evidence Record

The research provides context on what has been observed so far, but certain areas remain uncertain. A key limitation is the variation in evidence quality across studies for the many different manifestations of systemic candidiasis. While cryptococcal meningitis has been studied extensively with high-quality RCTs, the data supporting optimal combination structures for rarer systemic Candida infection sites are still emerging.

Additionally, as the drug is almost exclusively used in combination, the specific contribution of flucytosine in certain combination structures and for certain patient subgroups evidence contributes to understanding, rather than being defined by flucytosine-only trials. The need for more long-term follow-up and data for certain low-income settings research describes as key gaps.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Ancotil 500 mg (FAQ)


Q: Why is Ancotil usually prescribed along with Amphotericin B?

A: Flucytosine, the active ingredient in Ancotil, is usually administered in combination with another drug, such as Amphotericin B. This combination is described as leading to measurements of synergistic antifungal activity, which means the combined effect is greater than the sum of the individual drugs. Using them together is also a strategy to help prevent the fungal infection from developing resistance to Ancotil.

Q: Can Ancotil be used for common infections like athlete's foot?

A: Official product information states that Flucytosine is approved only for the treatment of serious systemic infections caused by susceptible strains of Candida and Cryptococcus. These are typically deep-seated, life-threatening infections, and the drug is not generally indicated for common, localized fungal conditions like athlete's foot.

Q: How quickly does Ancotil typically start to work on a systemic infection?

A: Regulatory information indicates that the drug is rapidly and largely absorbed following oral administration. Peak concentrations in the blood are generally reached within two to six hours after taking a dose. However, the overall clinical response to the infection is measured over the initial period of treatment, consistent with clinical protocols.

Q: Does Ancotil cause long-term side effects or are they temporary?

A: The official product labeling indicates that many common reactions, such as nausea or skin rash, are typically reversible once the medication is stopped. However, the most serious side effects, such as bone marrow suppression (which affects blood cell production), can be described as severe, irreversible, and potentially fatal. Regulatory guidelines require close monitoring for these risks throughout treatment.

Q: What is DPD deficiency, and why is it important for someone taking Ancotil?

A: DPD (Dihydropyrimidine Dehydrogenase) is an enzyme that helps the body break down the active substance derived from Flucytosine. If a patient has a known complete deficiency of this enzyme, Flucytosine is strictly contraindicated. This is because the drug would build up in the body and could lead to a high risk of life-threatening toxicity.

Q: Can Ancotil make my skin more sensitive to the sun?

A: Yes, photosensitivity, which is an increased sensitivity of the skin to sunlight, is listed as an adverse reaction that has been reported in patients using Flucytosine. When photosensitivity is present, it is often managed by limiting sun exposure.

Q: Are there any common foods or supplements that interact with Ancotil?

A: The drug label does not specify major interactions with common foods. However, official documentation states the importance of reviewing all prescription and nonprescription medicines, as well as vitamins, nutritional supplements, and herbal products, due to the potential for interactions.

Q: If I am taking herpes medication, can I still take Ancotil?

A: Official regulatory documents state that Flucytosine is contraindicated if you are currently taking or have recently taken certain drugs known as DPD inhibitors. This category includes specific antiviral antiherpetic nucleoside analogues such as brivudine or sorivudine. Reviewing all medications with a prescriber is a required safety measure.

Q: Is there an age limit for who can use Ancotil?

A: Safety and effectiveness have not been established across all age groups. In the pediatric population (children and adolescents), the drug requires extreme caution, dose adjustment, and strict monitoring when used. Data for use in elderly patients is also limited.

Q: Does Ancotil interact with common pain relievers or cold medicines?

A: The official drug information outlines specific, serious interactions with certain drug classes, but many medications can potentially interact. It is essential to check for interactions with all prescription and nonprescription medicines, including over-the-counter pain relievers and cold remedies.

Q: Is Ancotil considered a form of chemotherapy because of its chemical structure?

A: Flucytosine is officially classified as an antimetabolite and an antifungal agent. In the body, it is converted by the fungus into 5-fluorouracil (5-FU), which is a substance that is also used as an anti-cancer (cytostatic) agent in chemotherapy. This structural link is the reason it is sometimes associated with chemotherapy drugs.

Q: Does Ancotil cause weight changes?

A: Postmarketing safety reports have cited instances of both rapid weight gain and weight loss in connection with Flucytosine use. However, the frequency of these reports is not defined in the official labeling.

Q: Can Ancotil cause changes in mood or lead to depression?

A: The official documentation lists serious adverse reactions related to the nervous system, including confusion, hallucinations, and sedation. Additionally, postmarketing safety data cites reports of mood changes and depression in patients taking this medication.

Q: Does Ancotil affect blood sugar levels?

A: Yes, hypoglycemia (low blood sugar) is listed in the medication's adverse effects data. The frequency of this side effect is not generally defined in the official product information.

Q: Why is Ancotil sometimes combined with fluconazole instead of amphotericin B?

A: Flucytosine is used as part of several combination therapy structures. For example, in the treatment of cryptococcal meningitis, it is often used with Amphotericin B for the initial phase, and then a different antifungal like fluconazole may be used for the subsequent consolidation phase. The choice of combination structure is based on the specific infection and clinical guidelines.

Q: Are there generic versions of Ancotil available?

A: Yes, the FDA has approved generic versions of the drug containing the active ingredient flucytosine. These generic alternatives are available in 250 mg and 500 mg capsule strengths.

Q: Can Ancotil cause temporary growth issues in children?

A: Yes, regulatory-related safety data cites reports of temporary growth failure as an adverse effect associated with Flucytosine. If the medication is used in children, dose adjustments and strict monitoring are required.

Q: Does Ancotil change the color of urine or stools?

A: Changes to urine or stool color are not listed as common side effects of the drug itself. However, official information warns that serious side effects like liver problems may be accompanied by symptoms like dark urine or light-colored stools. Black or tarry stools may also indicate a serious gastrointestinal issue.

Q: What are the signs of a serious allergic reaction to Ancotil?

A: Signs of a serious allergic reaction (hypersensitivity) may include developing a rash or hives, itching, or swelling of the face, tongue, or throat. You may also experience wheezing or trouble breathing. These symptoms are recognized as a serious medical event.

Q: Why is the drug given by infusion sometimes instead of tablets?

A: The drug is available as both an oral tablet and an intravenous (IV) infusion solution. The IV route may be chosen when there is a need for rapid drug concentration in the bloodstream or if the patient is unable to take the medication by mouth. The IV formulation is often used in critical care settings.

Q: Does having liver impairment affect how my body handles Ancotil?

A: While the use of flucytosine in patients with existing hepatic (liver) impairment has not been fully studied, the official product information requires strict clinical and biological monitoring of liver function throughout treatment. This is because Flucytosine can cause liver damage, and pre-existing impairment may increase risk.

Q: Is there a test for DPD deficiency before starting treatment?

A: Pre-treatment testing for DPD deficiency is not required to avoid delaying urgent antifungal therapy. However, DPD activity determination is advised to be considered by the doctor if the patient develops confirmed or suspected drug toxicity during treatment.

Advertisements

How should Ancotil 500 mg be stored and disposed of?

Official Storage and Disposal Requirements

Ancotil 500 mg tablets must be stored under specific environmental and packaging conditions, as defined by regulatory labeling, to maintain product quality.

Storage Conditions

The medication must be stored below 25 C (or not above 30 C in certain regions) and requires protection from moisture. It is mandatory to keep the product in the original container and ensure the bottle is tightly closed; the desiccant canister inside the container must not be removed. The medication must be kept out of the reach of children.

Disposal Instructions

There are no special requirements noted for the disposal of the unused tablets. Any expired or unused Ancotil must be disposed of in accordance with local requirements for pharmaceutical waste, and should not be discarded via wastewater or standard household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Ancotil 500 mg found in:

A-Z Index: